Pharmacological inhibition or genetic ablation of CCR5 rescued mice from colitis in both acute and chronic models, hence the clinically-approved small molecule antagonist of CCR5, maraviroc may represent a novel approach to reducing the mucosal trafficking of blood leukocytes in human IBDs. The gene discussed is CCR5; the disease is colitis.